Chief Executive Officer

Dr. Sarraf founded Amydis in 2013 after seeing a clinical need for a novel technology to enable early detection of neurodegenerative diseases. She brings a blend of large pharmaceutical operational expertise, venture investment background and entrepreneurship to Amydis. Dr. Sarraf is viewed as a visionary with a deep understanding of “cradle to grave” and the necessary components to achieve success from product concept through to commercialization. Previously, she spent 10 years in Venture Capital at Foresite Capital Management and Prospect Venture Partners, both growth capital healthcare funds with over $1 billion dollars in assets under management. Earlier in her career, Dr. Sarraf worked at Merck Research Laboratories in Rahway, New Jersey as a senior research chemist responsible for creating the chemical synthesis of a novel drug for translation from the bench to production scale. In 2016, Dr. Sarraf founded Spinogenix, Inc., focused on developing novel neuroregenerative therapeutics. Dr. Sarraf holds a PhD in organic chemistry from Columbia University and earned a BA in biochemistry and molecular biology from the University of California, Berkeley.